Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing' vascular segments

Core Viewpoint - Penumbra's stock experienced a significant increase of approximately 14% following the announcement of a deal on Thursday morning [1] Group 1 - The announcement of the deal positively impacted Penumbra's stock performance, indicating strong market reaction [1]